254 related articles for article (PubMed ID: 18483264)
1. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells.
Contessa JN; Bhojani MS; Freeze HH; Rehemtulla A; Lawrence TS
Cancer Res; 2008 May; 68(10):3803-9. PubMed ID: 18483264
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy.
Contessa JN; Bhojani MS; Freeze HH; Ross BD; Rehemtulla A; Lawrence TS
Clin Cancer Res; 2010 Jun; 16(12):3205-14. PubMed ID: 20413434
[TBL] [Abstract][Full Text] [Related]
3. Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.
Baro M; Lopez Sambrooks C; Quijano A; Saltzman WM; Contessa J
Clin Cancer Res; 2019 Jan; 25(2):784-795. PubMed ID: 29967251
[TBL] [Abstract][Full Text] [Related]
4. Mannose phosphate isomerase regulates fibroblast growth factor receptor family signaling and glioma radiosensitivity.
Cazet A; Charest J; Bennett DC; Sambrooks CL; Contessa JN
PLoS One; 2014; 9(10):e110345. PubMed ID: 25314669
[TBL] [Abstract][Full Text] [Related]
5. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Ling YH; Li T; Perez-Soler R; Haigentz M
Cancer Chemother Pharmacol; 2009 Aug; 64(3):539-48. PubMed ID: 19130057
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
7. N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor.
Itkonen HM; Mills IG
PLoS One; 2013; 8(5):e65016. PubMed ID: 23724116
[TBL] [Abstract][Full Text] [Related]
8. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
9. Effects of membrane trafficking on signaling by receptor tyrosine kinases.
Miaczynska M
Cold Spring Harb Perspect Biol; 2013 Nov; 5(11):a009035. PubMed ID: 24186066
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
11. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
12. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
13. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.
Abounader R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):235-45. PubMed ID: 19192961
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
Yu L; Saile K; Swartz CD; He H; Zheng X; Kissling GE; Di X; Lucas S; Robboy SJ; Dixon D
Mol Med; 2008; 14(5-6):264-75. PubMed ID: 18231572
[TBL] [Abstract][Full Text] [Related]
15. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
16. Conserved roles for receptor tyrosine kinase extracellular regions in regulating receptor and pathway activity.
Gonzalez-Magaldi M; McCabe JM; Cartwright HN; Sun N; Leahy DJ
Biochem J; 2020 Nov; 477(21):4207-4220. PubMed ID: 33043983
[TBL] [Abstract][Full Text] [Related]
17. Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.
Lopez Sambrooks C; Baro M; Quijano A; Narayan A; Cui W; Greninger P; Egan R; Patel A; Benes CH; Saltzman WM; Contessa JN
Cancer Res; 2018 Sep; 78(17):5094-5106. PubMed ID: 30026325
[TBL] [Abstract][Full Text] [Related]
18. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks.
Wagner JP; Wolf-Yadlin A; Sevecka M; Grenier JK; Root DE; Lauffenburger DA; MacBeath G
Sci Signal; 2013 Jul; 6(284):ra58. PubMed ID: 23861540
[TBL] [Abstract][Full Text] [Related]
20. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
